BPC-157 (Body Protection Compound 157) is a 15-amino acid synthetic peptide derived from a protective protein found in human gastric juice. It has become one of the most widely researched peptides for tissue repair, with an exceptional safety profile across animal studies and growing anecdotal evidence in human research contexts.
Standard Dosing Protocol
The most commonly used research dose is 250–500mcg per injection, administered 1–2 times daily. For systemic effects (gut healing, anti-inflammatory, systemic tissue repair), subcutaneous injection in the abdominal area is standard. For localized injury repair, injection proximate to the injury site is preferred by many researchers.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Acute injury repair | 500mcg | 2x daily | SubQ near injury |
| Systemic / gut healing | 250–500mcg | 1–2x daily | SubQ abdominal |
| Maintenance / prevention | 250mcg | 1x daily | SubQ or oral |
Reconstitution
BPC-157 is typically supplied as a lyophilized (freeze-dried) powder in 2mg or 5mg vials. Standard reconstitution: add 2mL of bacteriostatic water to a 5mg vial = 2,500mcg/mL concentration. A 250mcg dose = 0.1mL (10 IU on a 100-unit insulin syringe). Always inject BAC water slowly down the side of the vial — never directly onto the powder.
Cycle Framework
For acute injuries: run a 4–8 week cycle at full dose, then assess. For chronic conditions or maintenance: lower doses (250mcg/day) can be used for extended periods — no receptor downregulation has been observed in research. Standard on/off: 8 weeks on, 2–4 weeks off.
What to Expect Week by Week
Week 1–2: Reduced inflammation at injury sites, improved gut comfort if used for GI issues. Week 3–4: Measurable improvement in tendon/ligament mobility and pain reduction. Week 5–8: Continued tissue remodeling, improved range of motion, potential systemic anti-inflammatory effects.